(Q46650489)

24 December 2017

title

Risk factors for leukemic transformation in patients with primary myelofibrosis (English)

1 reference

24 December 2017

0 references

1 reference

7

Ayalew Tefferi

1 reference

24 December 2017

Jocelin Huang

1

1 reference

24 December 2017

Chin-Yang Li

2

1 reference

24 December 2017

Ruben A Mesa

3

1 reference

24 December 2017

Wentling Wu

4

1 reference

24 December 2017

Curtis A Hanson

5

1 reference

24 December 2017

Animesh Pardanani

6

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

12

1 reference

24 December 2017

page(s)

2726-2732

1 reference

24 December 2017

Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Prognostic factors in idiopathic (primary) osteomyelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

A prognostic classification of myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Anaemia in myelofibrosis: its value in prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Do erythropoietin receptors on cancer cells explain unexpected clinical findings?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23505

7 January 2021

Identifiers

DOI

10.1002/CNCR.23505

1 reference

24 December 2017

1 reference

24 December 2017